547 related articles for article (PubMed ID: 33212810)
21. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
[TBL] [Abstract][Full Text] [Related]
23. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
Xu XJ; Zhao HZ; Tang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
[TBL] [Abstract][Full Text] [Related]
24. CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.
Narkhede M; Mehta A; Ansell SM; Goyal G
Ann Transl Med; 2021 Jun; 9(12):1036. PubMed ID: 34277836
[TBL] [Abstract][Full Text] [Related]
25. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
Nakazawa Y
Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
27. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
28. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
29. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
30. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
31. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.
Mochel JP; Ekker SC; Johannes CM; Jergens AE; Allenspach K; Bourgois-Mochel A; Knouse M; Benzekry S; Wierson W; LeBlanc AK; Kenderian SS
AAPS J; 2019 Apr; 21(3):50. PubMed ID: 30963322
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
33. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
34. Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
Roex G; Feys T; Beguin Y; Kerre T; Poiré X; Lewalle P; Vandenberghe P; Bron D; Anguille S
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32102267
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T cell treatment in hematologic malignancies.
Goker H; Malkan UY; Demiroglu H; Buyukasik Y
Transfus Apher Sci; 2016 Feb; 54(1):35-40. PubMed ID: 26874466
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Metzinger MN; Verghese C; Hamouda DM; Lenhard A; Choucair K; Senzer N; Brunicardi FC; Dworkin L; Nemunaitis J
Oncology; 2019; 97(2):59-74. PubMed ID: 31261152
[TBL] [Abstract][Full Text] [Related]
38. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
Ikeda H
Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
[TBL] [Abstract][Full Text] [Related]
39. Novel antigens of CAR T cell therapy: New roads; old destination.
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Transl Oncol; 2021 Jul; 14(7):101079. PubMed ID: 33862524
[TBL] [Abstract][Full Text] [Related]
40. [CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE].
Greenbaum U; Yehudai-Ofir D; Beyar Katz O; Shargian L; Jacoby E; Grisaru S; Zuckerman T; Ram R; Avigdor A
Harefuah; 2024 Apr; 163(4):236-243. PubMed ID: 38616634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]